Azenta’s beat is less about Q4 upside than FY2026 cash conversion the market has not paid for

The clean read from this print is that Azenta’s Q4 beat should not be treated as a one-quarter revenue surprise. What was priced in was modest upside against a cautious Street, with revenue expected at $156.2 million and EPS expected at $0.19. What actually surprised was a $159.2 million revenue print, a +1.9% surprise, and EPS of $0.21, a +10.8% surprise. The variant perception is that investors may still be anchoring on the company’s uneven revenue history and gross-margin volatility, when management is now offering a FY2026 setup where restrained top-line assumptions, 3% to 5% organic revenue growth, are paired with a much larger operating-income and cash-flow claim: 300 basis points of expected adjusted EBITDA margin expansion and over 30% year-over-year free cash flow improvement. That spread between modest growth and larger cash conversion is the crux of the long case, provided Q1 FY2026 does not expose the Q4 beat as timing rather than demand.

The reason the revenue beat matters is not its size, because +1.9% is not enough on its own to change a model. It matters because it came after four quarters in which the revenue base had been stuck around $147.4 million, $143.4 million, $143.9 million, and then $159.2 million. Q4 FY2025 revenue rose +10.6% QoQ and +5.7% YoY, which breaks the flat-to-down pattern that defined Q1 FY2025 through Q3 FY2025. The company’s own reported framing is consistent but not identical to the Street-comparison basis, so the distinction matters: Laurence Flynn said, “Fourth-quarter revenue was $159 million, up 6% year over year on a reported basis and up 4% organically, with Multiomics delivering a record quarter.” That wording earns attention because it explicitly ties the quarter’s growth to Multiomics rather than a broad-based demand rebound, which is both the opportunity and the risk. If Multiomics is the engine, then the Street should not capitalize the entire company at a generic tools multiple without separately underwriting whether record segment revenue is sustainable.

The financial trajectory also shows why the market’s instinct to fade the beat has some basis. Gross margin was 45.4% in Q4 FY2025, down from 47.1% in Q3 FY2025 and below 46.7% in Q1 FY2025, even as revenue jumped to $159.2 million. That means the quarter did not prove pure volume leverage at the gross line. The reported history is choppy: gross margin moved from 45.5% in Q4 FY2024 to 46.7% in Q1 FY2025, 45.9% in Q2 FY2025, 47.1% in Q3 FY2025, and 45.4% in Q4 FY2025. The company’s non-GAAP segment detail explains the conflict. SMS had $86 million of revenue, up 2% reported and flat organically, with non-GAAP gross margin of 49.3%, up 180 basis points year over year. Multiomics had $73 million of revenue, 11% reported growth and 10% organic growth, but non-GAAP gross margin of 43.7%, down 260 basis points year over year. The market may be missing that consolidated margin weakness is not evidence of an undisciplined company; it is the accounting consequence of the faster-growing segment carrying lower and falling segment gross margin in the quarter.

That segment mix creates a second-order read that is more nuanced than “growth is back.” Multiomics delivered the record revenue quarter, and management identified next-generation sequencing as the driver, with sequence volume rising 50% year over year. A 50% volume increase against 10% organic growth in Multiomics revenue implies meaningful mix, price, or service-intensity pressure without needing to invent a unit price. The important investment question is whether automation and capacity spending can convert that volume growth into margin in FY2026. Capital expenditures were approximately $8 million in the quarter, directed to automation, capacity expansion, and technology. Free cash flow, including B Medical, was a usage of $6 million in Q4, which management attributed to timing of revenue and project-related milestone billing. The quarter therefore contains both sides of the thesis: demand evidence in 50% sequence volume growth, and cash-timing friction in $6 million of free cash flow usage.

The bridge from Q4 to FY2026 is where the print becomes actionable, because management did not ask investors to underwrite a dramatic revenue acceleration. John Marotta committed to the operating model in a sentence that matters more than the Q4 revenue beat: “We anticipate core revenue growth between 3% to 5% and expected adjusted EBITDA margin expansion of 300 basis points, and higher free cash flow generation as we scale our operational improvements.” The market’s likely skepticism is that Azenta has not yet shown clean gross-margin expansion in the latest quarter, given 45.4% gross margin in Q4 FY2025 after 47.1% in Q3 FY2025. The counter is that adjusted EBITDA already moved in the right direction: adjusted EBITDA was $21 million, representing a 13% margin, while full-year adjusted EBITDA margin was 11.2%, and management cited expansion of approximately 230 basis points in Q4 and 310 basis points for the full year. If FY2026 margin expansion comes through on only 3% to 5% organic revenue growth, the debate shifts from revenue cyclicality to durability of process improvement.

The balance sheet gives Azenta time to prove that operating model, and that matters because the company is still cleaning up B Medical noise. Flynn disclosed an additional non-cash loss on assets held for sale of $4 million on B Medical, while full-year free cash flow was $38 million, an improvement of $26 million year over year. Excluding B Medical, the company ended the year with $546 million in cash, cash equivalents, and marketable securities. John Marotta’s own capital-allocation language was explicit: “The strength of our balance sheet, with over $500 million in cash, cash equivalents, and marketable securities, gives us the financial flexibility to invest with discipline across four strategic levers: driving productivity, accelerating organic growth, returning capital to shareholders through share repurchases, and pursuing targeted tuck-in M&A.” The key is not the phrase “financial flexibility”; it is the list. With $546 million available excluding B Medical, the company can fund automation and capacity, repurchase shares, and pursue tuck-in M&A without needing a heroic FY2026 revenue rebound.

That same capital-allocation setup has implications beyond Azenta, though the supply-chain data give only one named customer and no named suppliers. For TSMC, listed as a customer for wafer handling and automation equipment, the read-through is not that Azenta is forecasting semiconductor capex strength; the Q4 discussion is dominated by SMS and Multiomics, and SMS was only $86 million of revenue, up 2% reported and flat organically. The more defensible implication is capacity discipline rather than a sharp order-cycle inflection: Azenta’s approximately $8 million of quarterly capital expenditures went into automation, capacity expansion, and technology, while SMS non-GAAP gross margin improved to 49.3%, up 180 basis points year over year, despite flat organic growth. For TSMC’s supplier ecosystem, that combination points to selective automation productivity rather than broad wafer-handling demand acceleration. There are no named suppliers to Azenta in the data, so the supplier read-through stops there rather than pretending a vendor exposure that is not provided.

The peer comparison reinforces why investors should focus on Azenta’s margin structure, not just revenue growth. In the Fab_Subsystems peer set, 6856.T posted +17.6% revenue YoY with 43.8% gross margin, while 6368.T posted +4.9% revenue YoY with 38.9% gross margin and 6370.T posted -8.1% revenue YoY with 40.0% gross margin. Azenta’s Q4 FY2025 revenue YoY was +5.7% and gross margin was 45.4%, putting the company’s margin above those named peer gross margins while its revenue growth sits much closer to 6368.T than to 6856.T. The comparative point is not that Azenta is outgrowing the group; it is not, based on 6856.T’s +17.6% revenue YoY. The point is that Azenta’s gross-margin base gives operating leverage a credible starting point if the company can deliver 300 basis points of adjusted EBITDA margin expansion on 3% to 5% organic revenue growth.

The call delivery supported the thesis but did not remove the near-term timing risk. In the tone history, Q4 FY2025 sentiment was 0.22, down from 0.24 in Q3 FY2025, while guidance_tone improved to 0.41 from 0.34. That mix fits the print: management sounded more constructive on the guide than on the current environment. Q4 FY2025 tone_confidence was 0.39, up from 0.27 in Q3 FY2025, but below 0.50 in Q1 FY2025 and 0.44 in Q2 FY2025. Prepared_sentiment was only 0.03, while qa_sentiment was 0.18, and uncertainty was 49.0, below 53.3 in Q3 FY2025 but above 48.6 in Q1 FY2025. The delivery was therefore not promotional; it was a low-affect call with better guidance tone and moderate confidence, which makes the 3% to 5% organic growth and over 30% free cash flow guidance more credible than it would be if paired with elevated sentiment and low numeric support.

The main risk to the variant view is visible in management’s own cadence guidance. Flynn said Q1 FY2026 revenue is expected to decline approximately 1% to 2% year over year, which means the market will not have to wait long to test whether Q4’s $159.2 million was timing-aided. The reported quarterly history after Q4 FY2025 already shows why investors punish this name when the cadence slips: Q1 FY2026 revenue was $148.6 million, gross margin was 42.9%, and diluted EPS was -$0.34; Q2 FY2026 revenue was $144.8 million, gross margin was 42.8%, and diluted EPS was -$3.49. Those later figures conflict with the Q4 FY2025 exit-rate optimism and highlight the difference between management’s FY2026 framework and the early-quarter reported margin path. The thesis survives only if adjusted EBITDA and free cash flow improve despite gross margin pressure; it breaks if gross margin stays around 42.9% and 42.8% without visible offset below the gross line.

What should be priced in after this event is a company that can grow modestly and generate cash, not a company that has proven a broad revenue acceleration. The Q4 beat of +1.9% on revenue and +10.8% on EPS is helpful, but the investable surprise is the FY2026 combination of 3% to 5% organic revenue growth, 300 basis points of adjusted EBITDA margin expansion, and over 30% free cash flow growth against a $38 million full-year free cash flow base. Watch the next reported quarter against three hard markers: revenue versus the guided approximately 1% to 2% year-over-year decline, consolidated gross margin versus Q4 FY2025’s 45.4% and the later 42.9% level, and evidence that Multiomics can keep growth near the Q4 segment markers of $73 million revenue, 11% reported growth, 10% organic growth, and 50% sequence volume growth without another 260 basis points of segment gross-margin compression. Confirmation is not another small revenue beat; confirmation is adjusted EBITDA margin moving toward the promised 300 basis points of FY2026 expansion and free cash flow tracking above $38 million by over 30%. If Q1 instead shows revenue below the approximately 1% to 2% year-over-year decline guide, gross margin closer to 42.8% than 45.4%, and no cash-flow improvement after the Q4 usage of $6 million, the market will be right to treat Q4 as a timing bounce rather than the start of a cash-conversion rerating.